Ingenza has joined forces with leading universities and industrial partners to participate in the ConBioChem collaboration, a translational project focused on the development of novel platform technologies for the continuous bio-production of commodity chemicals.

The consortium, led by Professor Gill Stephens of the University of Nottingham, recently achieved success in the Industrial Biotechnology Catalyst – a multi-million pound competition funded by Innovate UK, BBSRC and EPSRC – resulting in the award of £3.46 million over a five-year period. The consortium includes industrial partners Ingenza, Lucite, the Centre for Process Innovation, Green Biologics and Chain Biotech – along with the University of Nottingham, University College London and the University of Cambridge – and aims to develop new industrial biotechnology-based routes to commodity chemicals, moving away from fossil fuel and petrochemical-derived building blocks. Project manager Andrew Wells from the University of Nottingham explained: “Our aim is to use synthetic biology approaches to develop sustainable technologies based on the continuous fermentation of genetically-modified cells, enabling the rapid and cost-effective production of commodity chemicals from renewable carbon sources. By using multi-scale modelling and establishing ‘plug and play’ biological processes, we can improve efficiency, helping to accelerate the implementation of scalable bio-based manufacturing processes that are commercially viable.”

For more information, visit www.ingenza.com or email sarah.scott@ingenza.com

About Ingenza

Ingenza is a worldwide leaders in the application of industrial biotechnology and synthetic biology, providing efficient scalable bioprocesses to manufacture chemicals, biologics, pharmaceuticals and biofuels, from sustainable sources. Its scientific and commercial activities are led by a management team with over 25 years’ experience in applied bioscience and the development and commercialisation of bio-based products. In addition to engaging in strategic partnerships to tailor its bioprocess services for clients, the company also licenses its proprietary bioprocess technologies.